Search This Blog

Wednesday 2 April 2014

Update on July 3-5 EACPT Cardiovascular Focus Meeting in the Netherlands

Following the well-attended EACPT international summer school in 2013 in Edinburgh, the next European Association for Clinical Pharmacology and Therapeutics [EACPT] update for young researchers is the 2014 EACPT Focus Meeting on 'Drugs to Fight Cardiovascular Damage'. The EACPT Focus Meeting will provide you with the opportunity to attend state of the art lectures from leading professionals and researchers, including hands-on workshops. 
Topics include ultrasound imaging of vascular injury (including a hands-on workshop), the microbiome and inflammation in the metabolic syndrome, targeting inflammation to prevent and treat atherosclerosis, diagnosis and therapy of adrenal hypertension, and protection against ischaemia-reperfusion injury.

This EACPT Cardiovascular Focus Meeting is of interest to clinical pharmacologists, pharmacologists, and other young scientists and clinicians interested in drug treatment of cardiovascular disease. You can listen here to podcasts with international delegates at the last EACPT summer meeting in Edinburgh in 2013.

The abstract deadline is April 15th - the top 5 ranked abstracts will be provided with free registration. Abstract submission is online on the Focus Meeting website. There are opportunities for both oral and poster presentations within the overall scientific program.  All abstracts presented at the meeting will be published in Clinical Therapeutics, the peer-reviewed Official Journal of the EACPT. 
Registration is now open - with preferential rates if you register by May 15th. A preferential accommodation rate is available through the Focus Meeting website.
The Scientific Programme is now online on the Focus Meeting website. The 2014 EACPT Focus Meeting takes place from July 3rd - 5th at the Radboud University Medical 
Radboud University Medical Centre, Nijmegen
Center in Nijmegen in the Netherlands. 
Visit the Clinical Therapeutics website.

No comments:

Post a Comment